The Effects of Dexmedetomidine to Postoperative Awakening and Extubation-related Changes in Blood Pressure
Primary Purpose
Hypertension
Status
Completed
Phase
Phase 4
Locations
Finland
Study Type
Interventional
Intervention
Dexmedetomidine
Saline (placebo)
Sponsored by

About this trial
This is an interventional prevention trial for Hypertension focused on measuring Dexmedetomidine, Postoperative Period, Airway extubation, Systolic Pressure
Eligibility Criteria
Inclusion Criteria:
- Patient has to be scheduled for aortic valve surgery OR previous AND coronary artery bypass
- Patient has to be 60 to 90 years of age
Exclusion Criteria:
- If a patient is unable to give informed concent to participate the study
- If a patient is allergic or otherwise hypersensitive to the drug used in the study
- If the patient has either insufficient kidney or insufficient liver function
Sites / Locations
- TAYS Sydänkeskus Oy (Heart Center CO. Tampere University Hospital)
Arms of the Study
Arm 1
Arm 2
Arm Type
Placebo Comparator
Active Comparator
Arm Label
Saline group
Dexmedetomidine group
Arm Description
Difference from the normal protocol actualizes at the point when propofol infusion is cut off. From there on the patient in this group receives saline infusion up to the point where 15 minutes have passed after the extubation procedure.
Difference from the normal protocol happens when normally the propofol infusion is cut off. From there on the patient in this group receives dexmedetomidine infusion up to the point where 15 minutes have passed after the extubation procedure.
Outcomes
Primary Outcome Measures
Highest value of systolic blood pressure during extubation period
The values of this variable will be collected from the point when propofol infusion is cut. This data will be used to estimate the base level of SAP for further analysis within this study.
Secondary Outcome Measures
Risk index calculated from systolic blood pressure value and time spent in that value.
With the risk index we are better able to assess the total risk of the high levels of blood pressure to the patient. The risk index is dependant on the time integral of the blood pressure, for which the zero-value may be calculated from average pre-extubation SAP level.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01871129
Brief Title
The Effects of Dexmedetomidine to Postoperative Awakening and Extubation-related Changes in Blood Pressure
Official Title
The Effects of Postoperative Dexmedetomidine Sedation to Haemodynamics During Extubation
Study Type
Interventional
2. Study Status
Record Verification Date
May 2017
Overall Recruitment Status
Completed
Study Start Date
June 2013 (Actual)
Primary Completion Date
April 2014 (Actual)
Study Completion Date
April 30, 2014 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Tampere University Hospital
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The postoperative removal of intubation tube induces a noticeable sympathic response and increase of blood pressure. The risk of complications is especially elevated with the patients having cardiac surgery. Though sedation inhibits the sympathetic responses to extubation, according to the current protocol the propofol infusion has to be discontinued well before extubation because of its inhibitory effects on breathing centers.
Dexmedetomidine is relatively new anesthesia drug. Dexmedetomidine is unique in its characteristic that it does not have the paralyzing effect on breathing. The aim of our study is to work out whether dexmedetomidine-extended propofol sedation over the extubation diminishes the aforementioned harmful effects of the extubation procedure.
Study design is prospective double-blinded randomized study. The investigators compare two groups of 25 patients (total 50), who are of 60-90 years of age and are having either aortic valve surgery or the mentioned accompanied with cardiopulmonary bypass operation. The first group receives dexmedetomidine infusion and the other receives placebo infusion after the end of propofol infusion.
The specific goal of the study is to figure what haemodynamic - mostly blood pressure related - changes can be observed when the postoperatively cut propofol infusion is continued with dexmedetomidine over the extubation procedure.
Our hypothesis is that by using dexmedetomidine supplemented sedation the normally notifiable peak in blood pressure may be avoided.
The study will be carried out completely in Cardiac ICU in Tampere University Hospital.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
Keywords
Dexmedetomidine, Postoperative Period, Airway extubation, Systolic Pressure
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
50 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Saline group
Arm Type
Placebo Comparator
Arm Description
Difference from the normal protocol actualizes at the point when propofol infusion is cut off. From there on the patient in this group receives saline infusion up to the point where 15 minutes have passed after the extubation procedure.
Arm Title
Dexmedetomidine group
Arm Type
Active Comparator
Arm Description
Difference from the normal protocol happens when normally the propofol infusion is cut off. From there on the patient in this group receives dexmedetomidine infusion up to the point where 15 minutes have passed after the extubation procedure.
Intervention Type
Drug
Intervention Name(s)
Dexmedetomidine
Other Intervention Name(s)
Dexdor
Intervention Description
Dexmedetomidine will be diluted into a saline solution to a recommended concentration of 4 micrograms per millilitre. The saline will then be initially administered at the rate of 0.5 micrograms/kg/h and from that point the amount will be reduced to the point where the patient breathes well and is calm (compare dexmedetomidine recommendation at 0.2-1.4 ug/kg/h). The infusion rate will then be approximately 1-10 ml/h for a patient of 80 kgs weight. The exact dosage cannot be predetermined because it differs in each individual. In the control group the infusion speed is matching.
Intervention Type
Other
Intervention Name(s)
Saline (placebo)
Other Intervention Name(s)
Saline 0,9%, Normal saline
Intervention Description
Saline placebo infusion will be adjusted the same fashion as the active comparator drug.
Primary Outcome Measure Information:
Title
Highest value of systolic blood pressure during extubation period
Description
The values of this variable will be collected from the point when propofol infusion is cut. This data will be used to estimate the base level of SAP for further analysis within this study.
Time Frame
Starting five minutes before the extubation, lasting up to 1.5 hours.
Secondary Outcome Measure Information:
Title
Risk index calculated from systolic blood pressure value and time spent in that value.
Description
With the risk index we are better able to assess the total risk of the high levels of blood pressure to the patient. The risk index is dependant on the time integral of the blood pressure, for which the zero-value may be calculated from average pre-extubation SAP level.
Time Frame
Starting at the point when propofol infusion is halted and lasting up to three hours after extubation.
10. Eligibility
Sex
All
Minimum Age & Unit of Time
60 Years
Maximum Age & Unit of Time
90 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patient has to be scheduled for aortic valve surgery OR previous AND coronary artery bypass
Patient has to be 60 to 90 years of age
Exclusion Criteria:
If a patient is unable to give informed concent to participate the study
If a patient is allergic or otherwise hypersensitive to the drug used in the study
If the patient has either insufficient kidney or insufficient liver function
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kati M Järvelä, MD PhD
Organizational Affiliation
TAYS Sydänkeskus Oy (Heart Center CO. Tampere University Hospital)
Official's Role
Principal Investigator
Facility Information:
Facility Name
TAYS Sydänkeskus Oy (Heart Center CO. Tampere University Hospital)
City
Tampere
ZIP/Postal Code
33521
Country
Finland
12. IPD Sharing Statement
Learn more about this trial
The Effects of Dexmedetomidine to Postoperative Awakening and Extubation-related Changes in Blood Pressure
We'll reach out to this number within 24 hrs